In this study, we investigated the capability of genetically modified people mesenchymal stem cell providing a single-chain antibody (scFv) on the surface against a cancer specific antigen, EGFRvIII, to boost the therapy of EGFRvIII expressing glioma cells in vivo. Your growth of beta-Actin Antibody U87-EGFRvIII has been specifically delayed in co-culture with hMSC-scFvEGFRvIII. A significant
(Read More…)




